SIX Financial Information

Enter Ticker Symbol:

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Repligen Corporation (RGEN : NSDQ)

• Company Description

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.
Number of Employees: 1,778

• Price / Volume Information

Yesterday's Closing Price: $113.54 Daily Weekly Monthly

20 Day Moving Average: 665,349 shares

Shares Outstanding: 56.26 (millions)

Market Capitalization: $6,387.53 (millions)

Beta: 1.07

52 Week High: $182.52

52 Week Low: $102.97

Short Interest Ratio:

% Price Change % Price Change Relative to S&P 500

4 Week -10.34% -11.92%

12 Week -3.40% -12.26%

Year To Date -21.12% -25.87%

• Address & Contact Information

Street Address Phone / Fax Email Address Web URL

41 SEYON STREET BUILDING 1 SUITE 100
-
WALTHAM,MA 02453
USA ph: 781-250-0111
fax: 781-250-0115 investors@repligen.com http://www.repligen.com

• General Corporate Information

Officers

Oliver Loeillot - Chief Executive Officer and Director
Tony J. Hunt - Executive Chair
Jason K. Garland - Chief Financial Officer
Nicolas M. Barthelemy - Director
Carrie Eglinton Manner - Director

Peer Information

Repligen Corporation (CORR.)
Repligen Corporation (RSPI)
Repligen Corporation (CGXP)
Repligen Corporation (BGEN)
Repligen Corporation (GTBP)
Repligen Corporation (RGRX)

Industry / Sector / Ticker Info

Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 759916109
SIC: 2836

Fiscal Year

Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/11/25

Share - Related Items

Shares Outstanding: 56.26
Most Recent Split Date: (:1)
Beta: 1.07
Market Capitalization: $6,387.53 (millions)

• EPS Information    • Dividend Information

Analyst Coverage: No Dividend Yield: 0.00%

Current Fiscal Quarter EPS Consensus Estimate: $0.42 Indicated Annual Dividend: $0.00

Current Fiscal Year EPS Consensus Estimate: $1.70 Payout Ratio: 0.00

Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00

Estmated Long-Term EPS Growth Rate: 32.00% Last Dividend Paid: NA - $0.00

Next EPS Report Date: 11/11/25

• Fundamental Ratios

P/E

Current FY Estimate: 66.88
Trailing 12 Months: 69.66
PEG Ratio: 2.09

Price Ratios

Price/Book: 3.09
Price/Cash Flow: 36.55
Price / Sales: 9.48

EPS Growth

vs. Year Ago Period: 12.12%
vs. Previous Quarter: -5.13%

Sales Growth

vs. Year Ago Period: 18.36%
vs. Previous Quarter: 7.80%

ROE

06/30/25 - 4.61
03/31/25 - 4.53
12/31/24 - 4.22

ROA

06/30/25 - 3.24
03/31/25 - 3.17
12/31/24 - 2.94

Current Ratio

06/30/25 - 8.59
03/31/25 - 6.79
12/31/24 - 8.41

Quick Ratio

06/30/25 - 7.32
03/31/25 - 5.79
12/31/24 - 7.28

Operating Margin

06/30/25 - 13.73
03/31/25 - 13.97
12/31/24 - 13.34

Net Margin

06/30/25 - -2.05
03/31/25 - -3.93
12/31/24 - -4.64

Pre-Tax Margin

06/30/25 - -2.02
03/31/25 - -3.53
12/31/24 - -4.26

Book Value

06/30/25 - 36.70
03/31/25 - 35.34
12/31/24 - 35.21

Inventory Turnover

06/30/25 - 2.37
03/31/25 - 2.16
12/31/24 - 2.02

Debt-to-Equity

06/30/25 - 0.26
03/31/25 - 0.27
12/31/24 - 0.27

Debt-to-Capital

06/30/25 - 20.56
03/31/25 - 21.06
12/31/24 - 21.04

Powered by Zacks Investment Research ©